Cargando…
Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study
Background: Ceftazidime/avibactam is a new cephalosporin/beta-lactamase inhibitor combination approved in 2015 by the FDA for the treatment of complicated intra-abdominal and urinary tract infection, hospital-acquired pneumoniae and Gram-negative infections with limited treatment options. Methods: I...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944595/ https://www.ncbi.nlm.nih.gov/pubmed/35326784 http://dx.doi.org/10.3390/antibiotics11030321 |
_version_ | 1784673754621673472 |
---|---|
author | Di Pietrantonio, Maria Brescini, Lucia Candi, Jennifer Gianluca, Morroni Pallotta, Francesco Mazzanti, Sara Mantini, Paolo Candelaresi, Bianca Olivieri, Silvia Ginevri, Francesco Cesaretti, Giulia Castelletti, Sefora Cocci, Emanuele Polo, Rosaria G. Cerutti, Elisabetta Simonetti, Oriana Cirioni, Oscar Tavio, Marcello Giacometti, Andrea Barchiesi, Francesco |
author_facet | Di Pietrantonio, Maria Brescini, Lucia Candi, Jennifer Gianluca, Morroni Pallotta, Francesco Mazzanti, Sara Mantini, Paolo Candelaresi, Bianca Olivieri, Silvia Ginevri, Francesco Cesaretti, Giulia Castelletti, Sefora Cocci, Emanuele Polo, Rosaria G. Cerutti, Elisabetta Simonetti, Oriana Cirioni, Oscar Tavio, Marcello Giacometti, Andrea Barchiesi, Francesco |
author_sort | Di Pietrantonio, Maria |
collection | PubMed |
description | Background: Ceftazidime/avibactam is a new cephalosporin/beta-lactamase inhibitor combination approved in 2015 by the FDA for the treatment of complicated intra-abdominal and urinary tract infection, hospital-acquired pneumoniae and Gram-negative infections with limited treatment options. Methods: In this retrospective study, we evaluate the efficacy of ceftazidime/avibactam treatment in 81 patients with Gram-negative infection treated in our center from January 2018 to December 2019. The outcome evaluated was 30-days survival or relapse of infection after the first positive blood culture. Results: the majority of patients were 56 male (69%), with median age of 67. Charlson’s Comorbidity Index was >3 in 58 patients. In total, 46% of the patients were admitted into the medical unit, 41% in the ICU, and 14% in the surgical ward. Of the patients, 78% had nosocomial infections, and 22% had healthcare-related infections. The clinical failure rate was 35%: 13 patients died within 30 days from the onset of infection. The outcome was influenced by the clinical condition of the patients: solid organ transplantation (p = 0.003) emerged as an independent predictor of mortality; non-survival patients most frequently had pneumonia (p = 0.009) or mechanical ventilation (p = 0.049). Conclusion: Ceftazidime–avibactam showed high efficacy in infections caused by MDR Gram-negative pathogens with limited therapeutic options. |
format | Online Article Text |
id | pubmed-8944595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89445952022-03-25 Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study Di Pietrantonio, Maria Brescini, Lucia Candi, Jennifer Gianluca, Morroni Pallotta, Francesco Mazzanti, Sara Mantini, Paolo Candelaresi, Bianca Olivieri, Silvia Ginevri, Francesco Cesaretti, Giulia Castelletti, Sefora Cocci, Emanuele Polo, Rosaria G. Cerutti, Elisabetta Simonetti, Oriana Cirioni, Oscar Tavio, Marcello Giacometti, Andrea Barchiesi, Francesco Antibiotics (Basel) Article Background: Ceftazidime/avibactam is a new cephalosporin/beta-lactamase inhibitor combination approved in 2015 by the FDA for the treatment of complicated intra-abdominal and urinary tract infection, hospital-acquired pneumoniae and Gram-negative infections with limited treatment options. Methods: In this retrospective study, we evaluate the efficacy of ceftazidime/avibactam treatment in 81 patients with Gram-negative infection treated in our center from January 2018 to December 2019. The outcome evaluated was 30-days survival or relapse of infection after the first positive blood culture. Results: the majority of patients were 56 male (69%), with median age of 67. Charlson’s Comorbidity Index was >3 in 58 patients. In total, 46% of the patients were admitted into the medical unit, 41% in the ICU, and 14% in the surgical ward. Of the patients, 78% had nosocomial infections, and 22% had healthcare-related infections. The clinical failure rate was 35%: 13 patients died within 30 days from the onset of infection. The outcome was influenced by the clinical condition of the patients: solid organ transplantation (p = 0.003) emerged as an independent predictor of mortality; non-survival patients most frequently had pneumonia (p = 0.009) or mechanical ventilation (p = 0.049). Conclusion: Ceftazidime–avibactam showed high efficacy in infections caused by MDR Gram-negative pathogens with limited therapeutic options. MDPI 2022-02-28 /pmc/articles/PMC8944595/ /pubmed/35326784 http://dx.doi.org/10.3390/antibiotics11030321 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Di Pietrantonio, Maria Brescini, Lucia Candi, Jennifer Gianluca, Morroni Pallotta, Francesco Mazzanti, Sara Mantini, Paolo Candelaresi, Bianca Olivieri, Silvia Ginevri, Francesco Cesaretti, Giulia Castelletti, Sefora Cocci, Emanuele Polo, Rosaria G. Cerutti, Elisabetta Simonetti, Oriana Cirioni, Oscar Tavio, Marcello Giacometti, Andrea Barchiesi, Francesco Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study |
title | Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study |
title_full | Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study |
title_fullStr | Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study |
title_full_unstemmed | Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study |
title_short | Ceftazidime–Avibactam for the Treatment of Multidrug-Resistant Pathogens: A Retrospective, Single Center Study |
title_sort | ceftazidime–avibactam for the treatment of multidrug-resistant pathogens: a retrospective, single center study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8944595/ https://www.ncbi.nlm.nih.gov/pubmed/35326784 http://dx.doi.org/10.3390/antibiotics11030321 |
work_keys_str_mv | AT dipietrantoniomaria ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT brescinilucia ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT candijennifer ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT gianlucamorroni ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT pallottafrancesco ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT mazzantisara ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT mantinipaolo ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT candelaresibianca ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT olivierisilvia ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT ginevrifrancesco ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT cesarettigiulia ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT castellettisefora ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT cocciemanuele ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT polorosariag ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT ceruttielisabetta ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT simonettioriana ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT cirionioscar ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT taviomarcello ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT giacomettiandrea ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy AT barchiesifrancesco ceftazidimeavibactamforthetreatmentofmultidrugresistantpathogensaretrospectivesinglecenterstudy |